Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| 6.7 | |
| 6.62 | |
| - | |
| 6.92 | |
| 6.5201 | |
| 0.66-14.3 | |
| 195 M | |
| 29 756 K | |
| 31 000 | |
| -0.2816 | |
| -0.939 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Let me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers hi...
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
